In vivo, verteporfin treatment effectively reduced tumor burden in the HR xenograft models, decreased p-STAT3 and PD-L1 expression, and increased apoptosis, underscoring the therapeutic potential of targeting the ROR2-YAP/TEAD axis to overcome trastuzumab resistance. This evidence concerns the gene ROR2 and neoplasm.